SGS Expands Bioanalytical Testing Capabilities in North America with Acquisition of CMIC, INC.
"
Biologics represent a high-growth segment of the pharmaceutical market, alongside continued demand for small molecule and emerging oligonucleotide therapies. At the same time, increased outsourcing across drug development and clinical trials is fueling growth in third-party bioanalytical testing services. These complex modalities - particularly biologics and oligonucleotides - require highly specialized analytical approaches and are subject to stringent regulatory oversight by agencies such as the U.S. Food and Drug Administration (FDA) and Health Canada. Against this context, the acquisition of CMIC, INC. works towards achieving SGS's Strategy 27 objective to double North American sales between 2023 to 2027 by responding to megatrends driving growth in the TIC industry – including increased regulation and expectations for safety, health and well-being.
SGS has been supporting the North American pharmaceutical industry for over 30 years across the full drug development life cycle. This regional expertise is complemented by a global network of 20+ laboratories across 11 countries, including 10 GLP-compliant sites, positioning SGS as one of the most comprehensive, wholly owned analytical laboratory networks serving the pharmaceutical and biotechnology sectors worldwide.
CMIC, INC. is a group company of CMIC HOLDINGS Co., Ltd. Following the acquisition, CMIC HOLDINGS Co., Ltd. will continue to collaborate with SGS through CMIC Pharma Science Co., Ltd., its consolidated subsidiary operating analytical laboratories in
About SGS
SGS is the world's leading Testing, Inspection and Certification company. We operate a network of over 2,500 laboratories and business facilities across 115 countries, supported by a team of over 100,000 dedicated professionals. With more than 145 years of service excellence, we combine the precision and accuracy that define Swiss companies to help organizations achieve the highest standards of quality, compliance and sustainability.
Our brand promise – when you need to be sure – underscores our commitment to trust, integrity and reliability, enabling businesses to thrive with confidence. We proudly deliver our expert services through the SGS name and a portfolio of trusted specialized brands, including Applied Technical Services, Brightsight, Bluesign and Nutrasource.
SGS is publicly traded on the SIX Swiss Exchange under the ticker symbol SGSN (ISIN CH1256740924, Reuters SGSN.S, Bloomberg SGSN SW).
View original content to download multimedia:https://www.prnewswire.com/news-releases/sgs-expands-bioanalytical-testing-capabilities-in-north-america-with-acquisition-of-cmic-inc-302790391.html
SOURCE SGS
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JuryBall Vegas Conference Brings Leading Trial Lawyers & Litigation Experts Together for Networking and Hands-On Big Data Education
- WestBond Reports Financial Results for the Quarter ended June 30, 2026
- Diamond Estates Wines & Spirits Reports First Quarter Fiscal 2027 Financial Results
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Definitive Agreement, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share